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Abstract
In this paper, we report that the PX domain-containing protein SNX16, a member of the sorting nexin family, is associated
with late endosome membranes. We find that SNX16 is selectively enriched on tubulo-cisternal elements of this membrane
system, whose highly dynamic properties and formation depend on intact microtubules. By contrast, SNX16 was not found
on vacuolar elements that typically contain LBPA, and thus presumably correspond to multivesicular endosomes. We
conclude that SNX16, together with its partner phosphoinositide, define a highly dynamic subset of late endosomal
membranes, supporting the notion that late endosomes are organized in distinct morphological and functional regions. Our
data also indicate that SNX16 is involved in tubule formation and cholesterol transport as well as trafficking of the
tetraspanin CD81, suggesting that the protein plays a role in the regulation of late endosome membrane dynamics.
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Introduction
It is generally accepted that some long-lived lipids are not
stochastically distributed in cellular membranes but are differen-
tially distributed in subcellular compartments. The cholesterol
content of the endoplasmic reticulum (ER) is low — sensing
cholesterol levels in the ER regulates the expression of cholesterol-
dependent gene expression — and increases from the Golgi
apparatus to the plasma membrane [1]. Together with glyco-
sphingolipids, cholesterol forms raft-like microdomains, which are
believed to play a role in numerous cellular processes in the plasma
membrane and other cellular membranes, including protein and
lipid sorting, signaling, infection and immunity [2]. Other lipids
also show restricted distributions, in particular the unconventional
phospholipid lysobisphosphatidic acid (LBPA) or bis-monoacylgly-
cerophosphate (BMP), which is abundant in late endosomes and
not detected elsewhere in the cell [3]. In addition, phosphoino-
sitides, signaling lipids that are typically very short-lived, are
distributed in different cellular territories, through the concerted
action of lipid kinases and phosphatases [4,5,6]. Typically,
PtdIns(4,5)P2 and PtdIns(3,4,5)P3 are present in the plasma
membrane, PtdIns(4)P in the Golgi, while PtdIns(3)P and
PtdIns(3,5)P2 are both present in endosomes.
The human genome encodes more than 60 proteins that
contain either one of two conserved motives, the FYVE or PX
domain, binding phosphoinositides that are phosphorylated at the
D-3 position of the inositol ring [7]. Most, if not all, PtdIns(3)P-
binding proteins that have been characterized are present on
early endosomal membranes, whether they contained a FYVE or
a PX domain, leading to the notion that PtdIns(3)P is restricted to
early endosomes. Consistently, endosomal PtdIns(3)P is mostly
synthesized by the PtdIns 3-kinase VPS34, which is itself an
effector of the small GTPase RAB5 that controls early endosome
dynamics [8]. Conversely, FYVE or PX domain-containing
proteins are expected to be restricted to early endosomes, where
some may exhibit differential distributions in specialized domains
or vesicle subpopulations depending on their protein partners
[9,10,11].
In this paper, we studied the PX domain-containing protein
SNX16, which was originally identified by homology with the PX
domain of SNX1 [12] and is a member of the sorting nexin family
[13]. We were intrigued by the observations that SNX16 is not
present on early endosomes, yet membrane association depends on
an intact PX domain, and is reversed by the PtdIns 3-kinase
inhibitor wortmannin. We found that SNX16 is selectively
enriched on tubulo-cisternal membranes of the late endosomal
system, which exhibit highly dynamic properties, depending on an
intact microtubule network. However, upon ectopic expression at
low levels, SNX16 was hardly found on LBPA-containing vacuolar
elements, presumably corresponding to multivesicular endosomes.
We conclude that SNX16 together with its partner phosphoino-
sitide define a highly dynamic subset of late endosome mem-
branes, underscoring the notion that late endosomes are organized
in distinct morphological and functional regions. Our data also
indicate that SNX16 is involved in the regulation of late endosome
membrane dynamics, and that this process in turn may control
late endosomal cholesterol homeostasis and tetraspanin transport
through the compartment.
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SNX16 is not present on early endosomes
To analyze the subcellular distribution of SNX16, cells were
transfected with constructs encoding for fluorescent SNX16 fusion
proteins and analyzed by light microscopy. The ectopically
expressed protein showed a punctate pattern reminiscent of
endosomes (Fig 1A and 1B, left) and a cytosolic pattern after
treatment with the PtdIns 3-kinase inhibitor wortmannin (Fig 1B,
right), suggesting that SNX16 becomes membrane-associated via
interactions with PtdIns(3)P. Indeed, mutation of SNX16 Arg144
to Ala — a conserved residue of the PX domain necessary for
PtdIns(3)P binding in p40
phox [14] — abolished membrane
association (Fig 1B, middle). This is fully consistent with previous
findings that SNX16 binds strictly PtdIns(3)P and no other
phosphoinositide or phospholipid [12]. These observations
suggested that SNX16 might be present on early endosomes that
contain the bulk of PtdIns(3)P. However, to our surprise, RFP-
SNX16 did not colocalize to any significant extent with GFP-
RAB5 (Fig 1A). This small GTPase, which controls early
endosome dynamics [15], is the best-accepted marker of early
endosomal membranes and distributes to the different early
endosome subpopulations that have been studied, including
APPL-containing endosomes [10]. We also failed to observe
significant colocalization of SNX16 fused to Venus, an improved
YFP variant that allows detection of very low protein amounts
[16], with any other early endosome marker tested, including the
transferrin receptor (TFR, Fig 1C) and EEA1 (Fig 1D). GFP-
SNX16 has been previously reported to distribute to both early
endosomes and late endosomes/lysosomes [12] or to early
endosomes [17], perhaps as a consequence of overexpression.
Finally, we tried to localize endogenous SNX16 with antibodies,
although it had not been previously possible to detect the protein
by immunofluorescence [12]. Beyond a relatively high back-
ground, these antibodies showed a punctate pattern by indirect
immunofluorescence (Fig S1), reminiscent of Venus-SNX16
distribution (Fig 1), and clearly recognized SNX16, since they
labeled ectopically expressed Venus-SNX16 (Fig S2). Much like
SNX16, which did not overlap with GFP-RAB5 (Fig 1A),
endogenous SNX16 did not colocalize with endogenous RAB5
(Fig S1A, and see below). The endogenous protein could be
detected with antibodies in our cells, presumably because it is
somewhat more abundant when compared to cells used in
previous studies [12].
SNX16 distributes to a subset of late endosomal
membranes
We investigated whether SNX16 was present on other
subcellular organelles, but did not observe colocalization with
markers of biosynthetic membranes (not show). By contrast,
Venus-SNX16 showed significant colocalization with LAMP1
(Fig 2A), an abundant glycoprotein of late endosomes and
lysosomes. Consistent with these data, an analysis by indirect
immunofluorescence with antibodies to SNX16 showed significant
colocalization of both endogenous SNX16 (Fig S1B) and Venus-
SNX16 (Fig S2A–C) with LAMP1. The presence of SNX16 on
late endocytic membranes was further supported by the observa-
tions that RFP-SNX16 showed significant colocalization with the
GFP-tagged version of RAB7 (Fig 2B), a small GTPase present on
late endosomes [15], and that Venus-SNX16 and RFP-RAB7
remained associated in time (Movie S1). To further investigate the
presence of SNX16 on late endocytic membranes, we made use of
the fact that overexpression of the RAB7 effector RILP causes late
endosomes to cluster in the pericentriolar region where they
remain immobile [18,19]. Typically, RFP-SNX16 co-clustered
with GFP-RILP (Fig 2C) within structures that remained
paralyzed in the pericentriolar region (Movie S2), and did not
contain the early endosomal marker EEA1 (Fig S3B). Moreover,
beyond the background of the antibody, GFP-RILP overexpres-
sion clearly caused endogenous SNX16 to co-cluster with GFP-
RILP and with LAMP1 (Fig S3A). Altogether these observations
demonstrate that SNX16 is present on late endosomal membranes
containing LAMP1 and RAB7.
To investigate SNX16 distribution in more detail we quantified
the colocalization of Venus-SNX16 with LAMP1 after 3D image
reconstruction of confocal sections with Imaris software. This
analysis revealed that approximately half of the Venus-SNX16
structures also contained LAMP1, while LAMP1 showed a
broader distribution with <20% present in SNX16-containing
membranes (Fig 3A–B). Surprisingly, we observed little colocaliza-
tion of Venus-SNX16 with the late endosome phospholipid LBPA
(Fig 2D, quantification in Fig 3A), while LBPA itself showed
extensive colocalization with LAMP1 (Fig 3A), as expected [20].
LBPA is abundant in the multivesicular regions of late endosomes
and is not detected elsewhere in the cell [20], raising the possibility
that multivesicular late endosomes do not contain significant
amounts of SNX16. Consistent with this notion, the tetraspanin
CD63, which is also abundant in multivesicular late endosomes
containing LBPA [21,22], showed only modest colocalization with
SNX16 (Fig 2E, quantification in Fig 3B), much like with LBPA.
CD63, however, showed extensive colocalization with LAMP1
(Fig 3B). We conclude that, while LBPA, CD63 and SNX16 are all
present in LAMP1- and RAB7-containing late endosomes, SNX16
distributes to membrane regions or elements that are largely
distinct from those containing LBPA and CD63.
The notion that SNX16 and LBPA distribute to different
membrane domains or subcompartments was strengthened
considerably by observations that membranes containing either
marker exhibited different physical properties in sucrose gradients.
After subcellular fractionation, the small GTPase RAB5 and
LBPA were enriched, as expected [23], in early and late endosome
fractions, respectively (Fig 3C). Surprisingly, SNX16 co-purified
with early endosomes containing RAB5 and not with LBPA-
containing late endosomes — and the protein had been previously
found in early endosome fractions [12]. Presumably, LBPA-
containing endosomes exhibit higher buoyancy on gradients (Fig 3)
because of the higher lipid to protein ratio of this multivesicular
compartment [22]. While LAMP1 did not co-purify with RAB5, a
very significant fraction of the total LAMP1 amounts (<50%) was
found in early endosomal fractions together with SNX16 (Fig 3D),
presumably corresponding to the membranes that contained both
LAMP1 and SNX16 but not LBPA (total amounts of LBPA are
much lower in early endosomal fractions than total LAMP1;
Fig 3D). From this analysis, we can conclude that SNX16-
containing membranes co-fractionate mostly with early endosomes
and not with the multivesicular late endosomes. Conversely, we
can also conclude that late endosomal membranes containing
LAMP1 can be separated into at least two subpopulations with
different physical properties on gradients, SNX16-containing
membranes and multivesicular late endosome elements containing
LBPA and tetraspanins.
Late endosome tubulo-cisternal regions
Since membranes containing SNX16 exhibit physical properties
that are different from multivesicular late endosomal membranes,
we wondered whether their appearance was also different. The
analysis of living cells by fluorescence video microscopy (Fig 2E
and see also below) suggested that a significant portion of SNX16
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PLoS ONE | www.plosone.org 2 July 2011 | Volume 6 | Issue 7 | e21771Figure 1. SNX16 is not present on early endosomal membranes. A) HeLa cells co-expressing EGFP-RAB5 and mRFP-SNX16 were analyzed by
fluorescence video microscopy. B) HeLa cells were transfected with EGFP-SNX16 or EGFP-SNX16
R144A and then treated or not with 100 nM
wortmannin for 30 min at 37uC, as indicated, and analyzed by fluorescence microscopy. C) HeLa cells were transfected with Venus-SNX16, fixed,
labeled with antibodies against TFR, and analyzed by fluorescence microscopy. D) HeLa cells were transfected with Venus-SNX16, fixed, labeled with
antibodies against EEA1, and analyzed by fluorescence microscopy.
doi:10.1371/journal.pone.0021771.g001
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PLoS ONE | www.plosone.org 3 July 2011 | Volume 6 | Issue 7 | e21771Figure 2. SNX16 is associated to a subset of late endosome membranes. A) HeLa cells were transfected with Venus-SNX16 and analyzed by
immunofluorescence microscopy using antibodies against LAMP1. B) HeLa cells co-expressing mRFP-SNX16 and EGFP-RAB7 were fixed and analyzed
by fluorescence microscopy (see also Movie S1). C) HeLa cells co-expressing mRFP-SNX16 and EGFP-RILP were analyzed by fluorescence video
microscopy (see Movie S2). D) HeLa cells transfected with Venus-SNX16 were analyzed by immunofluorescence microscopy using antibodies against
LBPA. E) HeLa cells were co-transfected with Venus-SNX16 and CD63-mRFP and analyzed by fluorescence video microscopy.
doi:10.1371/journal.pone.0021771.g002
SNX16 Membrane Domain of Late Endosomes
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structures that contain SNX16, cells expressing the Venus-tagged
protein were fixed with glutaraldehyde to better preserve the
ultrastructure, as is the case during sample preparation for electron
microscopy. Indeed, the ultrastructure of organelles, in particular
membrane tubules that are notoriously fragile, is not well
preserved after fixation in paraformaldehyde only. After fixation
in glutaraldehyde, SNX16 and LAMP1 overlapped significantly,
Figure 3. Analysis of SNX16 distribution by fluorescence microscopy and fractionation. A–B) HeLa cells transfected with Venus-SNX16
were labeled with antibodies against LAMP1 and LBPA (A) or LAMP1 and CD63 (B), and analyzed by confocal microscopy. The distribution of Venus-
SNX16 under low expression conditions, LAMP1, and LBPA (A) or Venus-SNX16, LAMP1, and CD63 (B) was quantified after 3D image reconstruction
using Imaris software (error bars indicate STDEVA). The data are expressed as the percentage of LAMP1, which co-distributes with the indicated
marker. C–D) Untransfected BHK cells were homogenized and a post-nuclear supernatant (PNS) was prepared. The PNS was fractionated by floatation
using a well-established step sucrose gradient [23]. Early (EE) and late (LE) endosome fractions were collected and analyzed by SDS gel
electrophoresis and western blotting with antibodies against LAMP1, SNX16 or RAB5, or by ELISA with antibodies against LBPA. In (C), the gels were
loaded with equal amounts of protein (2.5 mg), as were the wells in the ELISA analysis (5 mg), to visualize enrichment of the corresponding markers in
the fractions. RFU: relative fluorescence units. In (D), the gels were loaded with equal volume (1/3 of the total fraction) to visualize the yields of the
corresponding markers in the fractions. In the LBPA analysis, yields were calculated from the quantification of the ELISA data (total RFU).
doi:10.1371/journal.pone.0021771.g003
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(Fig 4B) much like in paraformaldehyde-fixed cells (Fig 4A).
Interestingly, SNX16 was also found within long tubulo-cisternal
elements that often extended over 1–2 mm (Fig 4B and C).
Moreover, it appeared that, while SNX16-positive tubules
frequently contained LAMP1 (Fig 4B, white arrows), some were
devoid of LAMP1 (Fig 4B, green arrows, and inset), suggesting
that SNX16-containing tubules can be heterogeneous in compo-
sition. Confocal microscopy analysis and 3D reconstruction with
Imaris software revealed that tubules decorated by Venus-SNX16
often contain LAMP1 (Fig 4C, right) and sometimes CD63 (not
shown) at discrete sites (arrows in Fig 4C), and not all along the
tubules. Since recycling endosomes also exhibit a tubular
morphology [24,25], we investigated whether the SNX16-positive
tubules that were devoid of LAMP1 originated from recycling
endosomes. Even in the absence of glutaraldehyde fixation,
brefeldin A causes a dramatic tubularization of early/recycling
endosomes containing the transferrin receptor [26] (Fig 4D). Yet,
the drug did not have any effect on SNX16 distribution,
demonstrating that the SNX16 tubules that did not contain
detectable levels of LAMP1 were not part of the early/recycling
endosome system. The effects of brefeldin A were confirmed by
labeling for p23, which re-distributed from its characteristic cis-
Golgi pattern (Fig 4D, bottom inset) to discrete perinuclear
punctae (Fig 4D), reminiscent of the ER-Golgi intermediate
compartment [27].
These observations indicate that SNX16 tubules themselves
may be somewhat heterogeneous in composition and may contain
varying amounts of LAMP1. To analyze the distribution of
SNX16 in more detail, cells were co-transfected with HRP-
LAMP1 [28] and Venus-SNX16. After fixation, HRP-LAMP1 is
easily revealed cytochemically using DAB as a substrate [28,29]
(Fig 5A). As expected from our immunofluorescence observations
(Fig 2–4), we found that a significant portion of SNX16 colocalized
with LAMP1 (Fig 5). In addition, this analysis also revealed that
SNX16-positive structures that did not contain detectable levels of
LAMP1 were frequently observed in close apposition to — and
often in continuity with — LAMP1-containing structures (high
magnification view in Fig 5D). Moreover, SNX16 and HRP-
LAMP1 were often found together on tubular profiles (Fig 5E
and F).
Dynamics of late endosome tubules containing SNX16
The nature of SNX16-containing tubular elements became
apparent when Venus-SNX16 was analyzed by time-lapse video
microscopy (Fig 6A and Movie S3). The protein was primarily
found in distinct elements with a characteristic tubulo-cisternal
morphology (arrows in Fig 6A) similar to those observed in
glutaraldehyde-fixed cells (Fig 4B–C), which distributed across the
entire cell cytoplasm and did not show preferential motion towards
the perinuclear region (Fig 6A and Movie S3), in contrast to the
characteristic centripetal motion of endosomal vesicles containing
internalized tracers. These elements aligned on microtubule tracks
(not shown) and exhibited high bidirectional motility (Movie S3)
that required the presence of polymerized microtubules (Fig 6B–
C). Indeed, in the absence of a polymerized microtubule network,
SNX16-positive structures exhibited only Brownian-like motion.
Moreover, tubules disappeared after nocodazole treatment, even
when analyzed in glutaraldehyde-fixed cells (Fig 7A), and SNX16
collapsed onto vesicles which remained immobile (Fig 6C). In
addition, microtubule depolymerization increased SNX16 coloca-
lization with LAMP1 by light microscopy (Fig 7A). Microtubule
depolymerization also increased SNX16 co-purification with
LBPA, which is present in multivesicular late endosomes with
low buoyancy after subcellular fractionation (see Fig 3), without
affecting early and late endosomal markers (Fig 7C). Presumably,
tubule formation no longer occurred after drug treatment, leading
to SNX16 accumulation on vesicular late endosomes.
Altogether, these observations further support the notion that
SNX16 distributes to specialized regions of late endosomal
membranes and indicate that microtubules not only support the
motility of SNX16-containing tubules but also their biogenesis
[30]. We conclude that late endosomes contain elements with
different composition, dynamic characteristics and physical
properties on gradients, and that SNX16 colocalizes with LAMP1
in highly dynamic tubulo-cisternal regions of the late endosome,
which typically lack the markers of multivesicular late endosomes
LBPA and CD63.
SNX16 overexpression interferes with the dynamics of
late endosomal tubules and trafficking through the
compartment
Biocomputing analysis does not predict the presence of a BAR
domain that senses or induces membrane curvature in SNX16, in
contrast to other members of the SNX family [31]. But SNX16
contains a predicted coiled-coil domain reminiscent of a BAR
domain. A hallmark of BAR-containing proteins is their capacity
to induce membrane tubulation upon overexpression [32,33].
However, SNX16 overexpression did not increase membrane
tubulation (Fig 7B), in marked contrast to SNX1 and other BAR
proteins, but caused the opposite effects. SNX16-positive struc-
tures appeared clustered upon overexpression in the perinuclear
region and SNX16 was no longer observed in tubules across the
cell cytoplasm (Fig 7B). Moreover, while SNX16 expressed at low
amounts did not colocalize with LBPA to any significant extent
(Fig 2 and 3), overexpression redistributed a significant portion of
SNX16 to LBPA-positive perinuclear endosomes (Fig 7B), and
increased SNX16 co-purification with LBPA-containing late
endosomes after fractionation (Fig 7D). Strikingly, overexpressed
GFP-SNX16 was found associated with multivesicular profiles in
electron micrographs (Fig 7E). In addition, an analysis by time-
lapse video microscopy revealed that the motility of endosomes in
cells overexpressing Venus-SNX16 (Movie S5) was significantly
reduced when compared to cells containing low levels of Venus-
SNX16 (Movie S4). To illustrate this effect, we color-coded the
first and last frames of the movies in green and red, respectively.
While green and red structures were readily visible in cells
expressing low levels of SNX16 (Fig 8A), indicating that
endosomes had moved during the sequence, mostly yellow
structures were observed after overexpression (Fig 8B). Quantifi-
cation of these sequences showed that the motility of endosomes
containing SNX16 was reduced approximately 5-fold (Fig 8C) in
cells expressing high levels of Venus-SNX16 (as in Fig 8B), when
compared to cells expressing low levels (as in Fig 8A). We thus
conclude that, much like after microtubule depolymerization,
SNX16 overexpression inhibits the biogenesis of late endosomal
tubules, leading to an accumulation of SNX16 on the vesicular
portions of late endosomes, which contain LBPA and are
abundant in the perinuclear region.
Others and us have shown that late endosomes play a crucial
role in the transport of LDL-derived cholesterol [34,35,36].
Cholesterol can be conveniently detected by fluorescence
microscopy using the cholesterol-binding drug filipin, which emits
in the UV range [37], and is normally present at low (below
detection) levels in late endosomes [3,30,38]. By contrast, in
<100% of the cells that overexpressed Venus-SNX16, cholesterol
showed a striking accumulation in late endosomes containing
SNX16 (Fig 8D) and other late endosomal markers (not shown).
SNX16 Membrane Domain of Late Endosomes
PLoS ONE | www.plosone.org 6 July 2011 | Volume 6 | Issue 7 | e21771Figure 4. SNX16 distribution after glutaraldehyde fixation, and after brefeldin A treatment. A–B) HeLa cells transfected with Venus-
SNX16 were fixed with paraformaldehyde (A) or glutaraldehyde (0.3%) and paraformaldehyde (3%) for 50 min (B) and analyzed by
immunofluorescence microscopy using antibodies against LAMP1. Green arrows point at Venus-SNX16-positive tubules without detectable LAMP1,
white arrows point to LAMP1- and SNX16-containing tubules. C) The left panel shows a confocal section of a cell expressing Venus-SNX16 and
labeled for LAMP1 (fixation as in B). The middle panel shows a 3D reconstruction of the corresponding confocal stack with Imaris software, and the
right panel shows a magnification of the boxed region, displaying only Venus-SNX16 and its colocalization with LAMP1. White arrows point out the
presence of LAMP1 at discrete sites of Venus-SNX16-decorated tubules. D) HeLa cells transfected with Venus-SNX16 were treated with brefeldin A
(5 mg/ml for 30 min) prior to fixation with paraformaldehyde and analyzed by immunofluorescence microscopy using antibodies against TFR and the
cis-Golgi protein p23. The insert in the p23 panel shows the characteristic ribbon-like distribution of p23 in control cells without brefeldin A.
doi:10.1371/journal.pone.0021771.g004
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disorder Niemann-Pick type C [3]. We were not able to investigate
in a conclusive manner the effects of SNX16 depletion with the
siRNAs that we have tested. However, it seems fair to conclude
from our overexpression data that SNX16, which distributes to a
highly dynamic subset of tubulo-cisternal late endosome mem-
branes, plays a role in late endosomal dynamics and thereby
regulates the trafficking of LDL-derived cholesterol in the
endosomal system. Moreover, the tetraspanin CD81, which
traffics through multivesicular endosomes [21], is normally present
on the cell surface [39,40], where it can readily be detected (Fig 8E,
upper panels). Much like cholesterol accumulation, in all cells that
overexpressed Venus-SNX16, CD81 was depleted from the cell
surface and redistributed to late endosomes containing SNX16
(Fig 8E, lower panels) and LBPA (Fig 7B). Thus, our data, in
agreement with our previous observations on endosome-to-cytosol
transport of viral nucleocapsids [41], indicate that cholesterol
transport and CD81 trafficking through late endosomes are
inhibited by excess SNX16.
Discussion
In this paper, we studied the PX domain-containing protein
SNX16, which is a member of the sorting nexin family. We find
that SNX16, in contrast to other PtdIns(3)P-binding proteins, is
not present on early endosomes, yet membrane association
depends on an intact PX domain, and is reversed by the PtdIns
3-kinase inhibitor wortmannin. SNX16 distributes to tubulo-
cisternal elements that are part of the late endosomal membrane
system, and not to multivesicular endosomes that typically contain
LBPA. In a previous study, SNX16 was found in both early and
late endosome fractions [12]. This observation agrees nicely with
our findings that SNX16 is restricted to a subpopulation of tubulo-
cisternal late endosomal membranes that co-purify with early
endosomes. We find that membranes containing SNX16 are
highly motile, and that these dynamic properties require
polymerized microtubules. However, when present in excess, we
also find that SNX16 distribution becomes shifted towards
multivesicular elements containing LBPA, with a concomitant
disappearance of the tubulo-cisternal elements.
Overexpressed SNX16 was previously found on early endo-
somes and was reported to stimulate EGF receptor degradation
[17]. However, others [12] and us (not shown) did not observe
such effects, perhaps suggesting that they resulted from high level
of SNX16 overexpression. We find that the accumulation of
SNX16 in LBPA-containing late endosomes — and the inhibition
of tubule formation — is accompanied by a Niemann-Pick Type
C-like accumulation of cholesterol in SNX16-containing late
endosomes and a re-distribution of the tetraspanin CD81 to these
SNX16-containing elements. Presumably, excess SNX16, by
interfering with endosome membrane dynamics, causes cholesterol
accumulation, which in turn interferes with sorting and trafficking
of CD81 molecules in transit through the compartment, leading to
their accumulation. Similarly, we had found that excess cholesterol
causes the accumulation of CD63, another member of the
tetraspanin family, in the late endosomes of endothelial cells
[42]. Moreover, we also found that endocytosed antibodies to
LBPA phenocopy the cholesterol accumulation observed in
Niemann-Pick Type C cells [3], without interfering with EGF
receptor degradation [43] — an effect reminiscent of overex-
pressed SNX16. Altogether, our data also fit nicely with our
previous observations that, during vesicular stomatitis virus
infection, excess SNX16 inhibits the delivery of viral RNA to
the cytoplasm, presumably by preventing the back-fusion of intra-
endosomal vesicles containing the viral RNA with the limiting
membrane [41] — a process that is also inhibited by cholesterol
accumulation in late endosomes [41,44]. We thus conclude that
SNX16, together with its partner phosphoinositide, define a highly
dynamic subset of late endosome membranes, and that excess
SNX16 interferes with this distinct morphological and functional
region and thereby affects cholesterol and CD81 trafficking
through the compartment in a selective manner.
SNX16 localization is surprising, since it contains a PX domain
that binds 3-phosphorylated inositides necessary for SNX16
membrane association, and since it selectively binds PtdIns(3)P
[12]. Yet, SNX16 distributes to late endosomal membranes. In
addition to PtdIns(3,4,5)P3 at the plasma membrane, mammalian
cells contain two other 3-phosphorylated inositides in the endocytic
pathway. PtdIns(3)P has only been found on early endosome
membranes, where the bulk of PtdIns(3)P is synthesized [8], and all
proteins that bind PtdIns(3)P that have been characterized to date
are present on early endosomal membranes. Mammalian cells also
contain PtdIns(3,5)P2, a phosphoinositide that accumulates under
hypertonic stress [45] and may be involved in autophagy [46]. The
steady state amounts of this lipid in the absence of stress are very
low, and its precise localization is debated. PtdIns(3,5)P2 is
synthesized from PtdIns(3)P via the PtdIns(3)P 5-kinase PIKFYVE,
which is itself a PtdIns(3)P-binding protein containing a FYVE
domain [45]. The distribution of PIKFYVE itself is also a matter of
debate. The current view is that PIKFYVE becomes associated to
early endosomes [47,48,49], but may also be transported elsewhere
[45]. However, knockdown of PIKFYVE had no effect on SNX16
distribution (not shown). It thus seems reasonable to conclude that
SNX16 binds a specific late endosomal pool of PtdIns(3)P via its PX
domain.
One possible explanation of our findings is that SNX16
becomes associated to early endosomes via PtdIns(3)P and then
remains endosome-associated during transport to late endosomes,
where SNX16 may accumulate via protein-protein interactions.
However, we did not detect SNX16 on early endosomes, including
under conditions that interfere with early-to-late endosome
transport, e.g. after microtubule depolymerization. An alternative
explanation is that SNX16 interacts on late endosomes with
unknown protein partners. Indeed, deletion of the coiled-coil
domain leads to decreased late endosomal localization and
increased association with early endosomes [12] (not shown).
Finally, if SNX16 interacts with PtdIns(3)P on late endosomes,
these PtdIns(3)P molecules may be synthesized locally by PtdIns 3-
kinase effectors of the late endosome small GTPase RAB7 [50].
One may also envision that late endosome PtdIns(3)P is derived
from a pool originally synthesized on early endosomes and
incorporated into intralumenal vesicles [51], which may eventually
be released on the late endosome limiting membrane via back-
Figure 5. HRP-LAMP1 and SNX16 distribution on tubular and vesicular late endosomes. A–F) HeLa cells co-transfected with Venus-SNX16
and HRP-LAMP1 were processed as described in [28,29]. Briefly, cells were chased with 1 mM DDT for 30 min, to ensure proper HRP-LAMP1
localization [28]. Prior to fixation, HRP-LAMP1 was revealed cytochemically with the DAB reaction and cells were permeabilized; each treatment was
for 30 min at 4uC under physiological osmolarity conditions [29]. Samples were analyzed by phase contrast microscopy to reveal HRP-LAMP1 (A) and
by fluorescence microscopy to reveal Venus-SNX16 (B). Panel C shows the merged image of A) and B), and panel D a high magnification view of the
region boxed in C). In E), an example of a cell is shown where Venus-SNX16 and HRP-LAMP1 colocalize on numerous tubules (magnification in F).
doi:10.1371/journal.pone.0021771.g005
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PLoS ONE | www.plosone.org 9 July 2011 | Volume 6 | Issue 7 | e21771Figure 6. Motility of Venus-SNX16-containing endosomes depends on microtubules. A) HeLa cells transfected with Venus-SNX16 were
analyzed by fluorescence video microscopy. Panel (A) shows a frame of Movie S3, which illustrates the dynamic tubulo-cisternal elements containing
SNX16. Arrows point at highly dynamic SNX16-positive tubules. B–C) HeLa cells transfected with EGFP-SNX16 were pretreated (C) or not (B) with 10 mM
nocodazole for 2 h, and analyzed by time-lapse video microscopy for 30 sec in the presence (C) or absence (B) of nocodazole. In the left panels, the first
(green)andlast(red)frameswerecolor-codedandsuperimposed.Thepresenceofeachcolorindicatesthatvesiclesmovedwhileyellowshowsthatthey
remained motionless. All frames superimposed without color-code shown in the right panels feature the trajectories of the corresponding vesicles.
doi:10.1371/journal.pone.0021771.g006
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PLoS ONE | www.plosone.org 10 July 2011 | Volume 6 | Issue 7 | e21771Figure 7. SNX16 distribution in the absence of polymerized microtubules, and re-localization to LBPA-containing multivesicular
late endosomes upon overexpression. A) HeLa cells transfected with Venus-SNX16 were treated or not with 10 mM nocodazole to depolymerize
the microtubules as in Fig 6, fixed in 0.3% glutaraldehyde and 3% paraformaldehyde, and analyzed by immunofluorescence microscopy using
antibodies against LAMP1. B) HeLa cells overexpressing Venus-SNX16 were analyzed by immunofluorescence microscopy using antibodies against
LBPA. C) BHK cells treated or not with nocodazole as in (A) were fractionated as in Fig 3. Early (EE) and late (LE) endosome fractions were analyzed by
SDS gel electrophoresis and western blotting using the indicated antibodies. Gels were loaded with equal amounts of protein. D) BHK cells
overexpressing myc-SNX16 were fractionated and analyzed as in (C). E) EGFP-SNX16-overexpressing cells were processed for cryosectioning and
labeled with anti-GFP antibodies, as described [56,57]. Scale bar is 100 nm.
doi:10.1371/journal.pone.0021771.g007
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PLoS ONE | www.plosone.org 11 July 2011 | Volume 6 | Issue 7 | e21771Figure 8. Overexpressed SNX16 inhibits late endosomal dynamics, and interferes with cholesterol and CD81 trafficking. A–B) HeLa
cells expressing either low (A; Movie S4) or high (B; Movie S5) levels of Venus-SNX16 were analyzed by time-lapse video microscopy for 30 sec. The
first (green) and last (red) frames were color-coded and superimposed, as in Fig 6B–C. C) The motility of Venus-SNX16-positive structures, depending
on SNX16 expression levels (including medium SNX16 expression), was quantified and expressed as a percentage of the motility observed at low
Venus-SNX16 expression (error bars indicate SEM). D) After Venus-SNX16 overexpression, HeLa cells were analyzed by fluorescence microscopy using
filipin to reveal the distribution of cholesterol. E) CD81 distribution was analyzed by fluorescence microscopy in cells with low Venus-SNX16 (upper
panels) or high Venus-SNX16 (lower panels) expression levels.
doi:10.1371/journal.pone.0021771.g008
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PtdIns(3)P is synthesized on early or late endosomes or whether
it is released by back-fusion, it is attractive to propose that
PtdIns(3)P-containing sites give rise to nascent tubules upon
SNX16 recruitment and further stabilization by protein-protein
interactions. Overexpression of SNX16 may interfere with the
process by titrating out components that are necessary for tubule
biogenesis, including perhaps PtdIns(3)P itself. This situation may
inhibit the transport of cholesterol by reducing the dynamic
properties of endosomal membranes, leading to CD81 re-
distribution from the cell surface to LBPA-containing multivesic-
ular late endosomes and NPC-like cholesterol accumulation. In
turn, cholesterol accumulation may inhibit the delivery of vesicular
stomatitis virus RNA to the cytoplasm during viral infection,
without interfering with transport to the lysosomes [12] (not
shown), as observed previously [43].
This scenario is attractive, since it provides a simple framework
for the regulation of late endosome membrane dynamics. Indeed,
late endosomal membranes at steady state undergo concomitant
deformation in two opposite directions, towards the endosome
lumen during intralumenal vesicle biogenesis and towards the
cytoplasm during the formation of SNX16-containing tubules. Both
processes must be controlled and integrated to ensure that
membrane homeostasis is maintained. Given the key role of
phosphoinositidesinendosomedynamics,itisattractivetospeculate
that such homeostatic process is under the control of PtdIns(3)P
signaling via specific effectors, including SNX16 in late endosomes.
Materials and Methods
Cells, antibodies, reagents and constructs
HeLa and BHK cell maintenance was described [52], as was the
mouse monoclonal anti-LBPA antibody [20]. We are very grateful to
Reinhard Jahn (Go ¨ttingen, Germany) for the mouse monoclonal
antibody against RAB5, and to Wanjin Hong (Singapore, Singapore)
for rabbit polyclonal antibodies against SNX16. Mouse monoclonal
anti-CD63 (1B5) was a kind gift of Mark Marsh (London, UK).
Rabbit polyclonal anti-p23 was described previously [27]. We also
used mouse monoclonal antibodies against transferrin receptor
(Zymed Laboratories, South San Francisco, CA), rabbit polyclonal
anti-EEA1 (Enzo Life Sciences, Plymouth Meeting, PA), mouse
monoclonal anti-EEA1 (BD Biosciences, Franklin Lakes, NJ), mouse
monoclonal anti-human LAMP1 (CD107a; BD Biosciences) and
rabbit polyclonal anti-human LAMP1 (Thermo Fisher Scientific,
Waltham, MA). HRP-labeled secondary antibodies were from
Amersham [53] or Sigma-Aldrich (St Louis, MO) and fluorescently
labeled secondary antibodies from Jackson Immunoresearch Labo-
ratories (West Grove, PA). Wortmannin, nocodazole, brefeldin A,
paraformaldehyde, glutaraldehyde, filipin, diaminobenzidine (DAB)
and o-dianisidine were from Sigma-Aldrich (St Louis, MO).
We obtained EGFP-RAB5 and EGFP-RAB7 from Marino
Zerial (Dresden, Germany), mRFP-RAB5 and mRFP-RAB7 from
Ari Helenius (Zurich, Switzerland), EGFP-RILP from Cecilia
Bucci (Lecce, Italy), HRP-LAMP1 from Matt Russell (Boulder,
Colorado), and dMYC-SNX16 from Wanjin Hong (Singapore,
Singapore). SNX16 was introduced into pEGFP-C2 or fused with
monomeric RFP or Venus, kindly provided by Atsushi Miyawaki
(Wako City, Saitama, Japan). CD63-expressing constructs were a
kind gift from Cynthia Leifer (Ithaca, NY).
Microscopy
Immunofluorescence microscopy has been described [54]. When
indicated, cells analyzed by immunofluorescence microscopy were
fixed with glutaraldehyde [55]. Pictures were captured using a Zeiss
Axiophot wide field microscope equipped with a Zeiss 63x Plan-
NEOFLUAR objective, a Leica AS MDW wide field microscope with
a Leica 63x Plan-APOCHROMAT glycerol immersion objective, a
Leica AF6000 LX wide field microscope with a Leica 100x Plan-
APOCHROMAT oil immersion objective, or a Leica TCS SP2
AOBS confocal microscope equipped with a Leica 100x Plan-
APOCHROMAT oil immersion objective. Time-lapse video micros-
copy was as described [30]. For 2-channel video microscopy,
acquisition was at a frame rate of 1 fps, single channel image
acquisition was at 5–6 fps. All movies show a time sequence of 30 sec,
accelerated 5-fold (movie length of 6 sec). The distribution of HRP-
LAMP1 was revealed cytochemically with DAB as a substrate and
visualized by phase contrast light microscopy [28,29]. Sample
preparation for electron microscopy was described previously [56,57].
For quantification of colocalization, 3D image analysis was
carried out with Imaris software (Bitplane, Zurich, Switzerland).
Briefly, image stacks obtained by confocal microscopy were
reconstructed with Imaris into 3D ‘‘surface objects’’ for each
channel. Colocalization of ‘‘surface objects’’ from different channels
was determined, and expressed as a percentage of the volume of the
LAMP1 3D reconstruction. For quantification of Venus-SNX16-
positive structure dynamics, the net movement was determined with
ImageJ software by subtracting the first frame from the last frame of
the image sequence — particle tracking was not feasible at high
Venus-SNX16 expression levels due to clustering which resulted
into visually merged compartments. The mean pixel intensity of the
resulting image, showing only structures that had moved, was
normalized to the mean pixel intensity of the first frame. Movement
at medium or high Venus-SNX16 expression levels were expressed
as a percentage of the movement at low Venus-SNX16 levels.
Other methods
Cells were transfected with FuGene (Roche Diagnostics, Basel,
Switzerland) according to manufacturer’s instructions. Microtu-
bules were depolymerized with 10 mM nocodazole for 2 h [23,52].
Early and late endosome fractionation by flotation in a sucrose
step gradient was described [23]. Cholesterol was revealed using
filipin as described [3], treatment with brefeldin A was described
in [27], and LBPA measurement by ELISA was reported in [20].
Supporting Information
Figure S1 Immunocytochemistry with anti-SNX16 anti-
bodies. Untransfected HeLa cells were fixed and analyzed by
immunofluorescence microscopy using antibodies against SNX16
and RAB5 (A) or LAMP1 (B).
(TIF)
Figure S2 Labeling of cells expressing Venus-SNX16
with anti-SNX16 antibodies. HeLa cells transfected with
Venus-SNX16 were fixed and analyzed by immunofluorescence
microscopy using antibodies against SNX16 and LAMP1. The
upper panels (A) show all channels, the middle panels (B) show
Venus-SNX16 and anti-SNX16 labeling, and the lower panels (C)
show anti-SNX16 staining and LAMP1.
(TIF)
Figure S3 Overexpression of the RAB7 effector RILP
clusters SNX16 in the perinuclear region, but not EEA1.
(A) HeLa cells transfected with EGFP-RILP were fixed and
analyzed by immunofluorescence microscopy using antibodies
against SNX16 and LAMP1. (B) HeLa cells transfected with
EGFP-RILP and mRFP-SNX16 were fixed and analyzed by
immunofluorescence microscopy using antibodies against EEA1.
(TIF)
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PLoS ONE | www.plosone.org 13 July 2011 | Volume 6 | Issue 7 | e21771Movie S1 Venus-SNX16 and mRFP-RAB7 colocalize on
late endosomes. HeLa cells co-expressing Venus-SNX16
(green) and mRFP-RAB7 (red) were analyzed by fluorescence
video microscopy. Shown is a detail in the cell periphery. Yellow
color in the merged panel (right) indicates colocalization in
peripheral late endosomes. Image acquisition was at a frame rate
of 1 fps for 30 sec.
(AVI)
Movie S2 Overexpression of the RAB7 effector RILP re-
distributes the majority of SNX16 to the perinuclear,
RILP-induced late endosomal cluster. HeLa cells co-
expressing mRFP-SNX16 (red) and EGFP-RILP (green) were
analyzed by fluorescence video microscopy (see Fig 2C). Yellow
color in the merged panel (right) indicates re-distribution of
SNX16-containing endosomes to the RILP-induced late endoso-
mal cluster in the perinuclear region around the MTOC [18,19].
Image acquisition was at a frame rate of 1 fps for 30 sec.
(AVI)
Movie S3 Motility of SNX16-containing membranes.
After Venus-SNX16 expression in HeLa cells, the dynamic
properties of SNX16-containing endosomes were analyzed by
high resolution time-lapse video microscopy (see Fig 6A). Image
acquisition was at a frame rate of 6 fps for 30 sec.
(AVI)
Movie S4 Motility of Venus-SNX16-positive membranes
in cells expressing low levels of Venus-SNX16. HeLa cells
with low Venus-SNX16 expression levels were analyzed by time-
lapse video microscopy (see Fig 8A). Image acquisition was at a
frame rate of 5 fps for 30 sec.
(AVI)
Movie S5 Motility of Venus-SNX16-positive membranes
in cells expressing high levels of Venus-SNX16. HeLa cells
with high Venus-SNX16 expression levels were analyzed by time-
lapse video microscopy (see Fig 8B). Image acquisition and analysis
were as for movie 4, to allow direct comparison of SNX16
motility.
(AVI)
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